A Faegre Drinker team led by corporate partners Matt Stamski and Brandon Mason advised medical device company Boston Scientific in its acquisition of Relievant Medsystems, Inc., a privately held medical technology company that has developed and commercialized the Intracept® Intraosseous Nerve Ablation System. The transaction includes an upfront payment of $850 million and undisclosed additional contingent payments based on sales performance over the next three years and is anticipated to close in the first half of 2024, subject to customary closing conditions.
A cross-office team of attorneys supported Stamski and Mason on this transaction, including corporate partner Vanessa Tabler and associates Tyler Griffin, Christina Lidondici and Conor White; benefits and executive compensation partner Gayle Skolnik and associate Mark Rosenfeld; government and regulatory partner Reed Abrahamson and associate Carly Helman; health care partners Amy Johnson and Steve Lokensgard and associate Aliyah Price; intellectual property partners Robert Leonard and Timothy Grimsrud and associates Darnell Cage, Tamara Criss and Kelly Young; labor and employment partner Dan Prokott, counsel Rhiannon Beckendorf and associate Kristin Halsing; real estate counsel Shane Barnes; and tax partner Sean FitzGerald and associate Lisa Okragly.
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 40 years, the company advances science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare.
Read Boston Scientific’s press release for more information on the deal.